Telo Genomics Gears up for American Society of Hematology Conference
Telo Genomics Gears up for American Society of Hematology Conference
Toronto, Ontario--(Newsfile Corp. - December 6, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA), (the "Company" or "Telo"), an emerging molecular testing platform provider leveraging the power of telomeres, looks forward to attending the American Society of Hematology (ASH) annual meeting in San Diego this week. The Company will present the repeatability analytical validation data of its lead product TeloViewSMM, while interacting with a global group of physicians and researchers and educating on the importance of telomere-based assessment of Smoldering Multiple Myeloma (SMM).
安大略省多倫多--（新聞文件公司-2023 年 12 月 6 日）- Telo Genomics Corp.（多倫多證券交易所股票代碼：TELO）（場外交易代碼：TDSGF）（FSE：3DOA），（這 “公司” 要麼 “Telo”）， 一家利用端粒力量的新興分子測試平台提供商期待着參加本週在聖地亞哥舉行的美國血液學會（ASH）年會。該公司將展示其主要產品TeloViewSMM的可重複性分析驗證數據，同時與全球醫生和研究人員進行互動，並就基於端粒評估悶燒多發性骨髓瘤（SMM）的重要性進行教育。
The 2023 ASH meeting taking place between December 9-12, 2023 in San Diego, USA, is an important milestone for Telo Genomics, as the Company offers it's TeloViewSMM assay to clinicians for the first time as a commercially available product. TeloViewSMM is a non-invasive liquid biopsy, featuring 3D telomere analysis, that utilizes the TeloView software platform to quantify genomic instability and transformation risk. The assay is a laboratory developed test, conducted at Telo's high-complexity ISO 15189 certified lab in Toronto.
2023年ASH會議將於2023年12月9日至12日在美國聖地亞哥舉行，這是Telo Genomics的重要里程碑，因爲該公司首次將其TeloViewsM檢測作爲市售產品提供給臨床醫生。TeloViewSMM 是一種非侵入性液體活檢，具有三維端粒分析功能，它利用 TeloView 軟件平台來量化基因組不穩定性和轉化風險。該測定是實驗室開發的測試，在多倫多Telo的高複雜度ISO 15189認證實驗室進行。
Telo Genomics CEO Kris Weinberg commented on the excitement within the company surrounding ASH attendance and lauded his team for their efforts "Through a lot of hard work and creative energy, we are bringing TeloViewSMM to the audience at ASH. Our entire team is dedicated to improving disease management and outcomes for patients diagnosed with Smoldering Multiple Myeloma."
Telo Genomics首席執行官克里斯·溫伯格評論了公司內部對ASH出席情況的興奮，並讚揚了他的團隊所做的努力：“通過大量的辛勤工作和創造力，我們正在將TeloViewSM帶給ASH的觀衆。我們的整個團隊致力於改善被診斷患有悶燒性多發性骨髓瘤的患者的疾病管理和預後。”
About the TeloView Platform
關於 TeloView 平台
TeloViewSMM is the first marketed product/use case in the TeloView platform portfolio. As the core enabling technology of the portfolio, TeloView uses quantitative analysis of 3D telomeres in combination with molecular biology and artificial intelligence to recognize disease associated genetic instability. The novel biomarkers enabled by the TeloView platform quantify the risk of cancer progression beyond standard phenotypic measures and are additive to standard molecular analysis. The utility of TeloView as both a research and clinical tool has been substantiated in over 160 peer reviewed publications and 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease.
TeloViewSMM 是 TeloView 平台組合中第一個上市的產品/用例。作爲產品組合的核心支持技術，TeloView將三維端粒的定量分析與分子生物學和人工智能相結合，來識別與疾病相關的遺傳不穩定性。TeloView平台支持的新型生物標誌物可以量化超出標準表型測量值的癌症進展風險，並且是標準分子分析的補充。TeloView作爲研究和臨床工具的實用性已在160多份同行評審出版物和涉及3,000多名多種癌症和阿爾茨海默氏病患者的30多項臨床研究中得到證實。
About TeloViewSMM
關於 TeloViewsmm
TeloViewSMM is a first-in-class telomere-based molecular tool that integrates proprietary quantitative analytics and artificial intelligence to evaluate the 3D organization of telomeres as a predictor of disease transformation in Smoldering Multiple Myeloma (SMM). The proprietary assay (and associated platform technology) quantifies risk of transformation/progression beyond standard phenotypic measures. Over 200,000 patients in the United States are currently living with smoldering Multiple Myeloma. The TeloViewSMM assay has a potential total addressable market of over 500,000 tests per year.
TeloViewSMM 是一款業界首款基於端粒的分子工具，它集成了專有的定量分析和人工智能，可評估作爲陰燃性多發性骨髓瘤 (SMM) 疾病轉變預測指標的端粒的三維組織。專有檢測（及相關的平台技術）量化了超出標準表型測量值的轉化/進展風險。目前，美國有超過20萬名患者患有悶燒的多發性骨髓瘤。TeloViewSMM測定的潛在潛在潛在市場每年超過50萬次測試。
About Telo Genomics
關於 Telo Genomics
Telo Genomics Corp. is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and predictive/prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, TeloView-MM is being developed to provide important, actionable information to medical professionals in the treatment of multiple myeloma, a deadly form of blood cancer. For more information, please visit .
Telo Genomics Corp. 是一家生物技術公司，憑藉強大的應用程序和預測/預測解決方案，開創了業內最全面的端粒平台。其中包括腫瘤學和神經系統疾病的液體活檢和相關技術。液體活檢是一個快速增長的領域，引起了醫學界的濃厚興趣，因爲與傳統的診斷方法相比，液體活檢的侵入性更小，更容易複製。通過將我們團隊在三維端粒定量分析方面的豐富專業知識與分子生物學和人工智能相結合，以識別與疾病相關的遺傳不穩定性，Telo正在開發簡單而準確的產品，通過滿足病理學家、臨床醫生、學術研究人員和藥物開發人員的需求，改善患者的日常護理。我們專有技術的益處已在 160 多篇同行評審出版物和 30 多項臨床研究中得到證實，涉及 3,000 多名患有多種癌症和阿爾茨海默病的患者。我們的主要應用程序TeloView-mm正在開發中，旨在爲治療多發性骨髓瘤（一種致命的血液癌）的醫療專業人員提供重要、可操作的信息。欲了解更多信息，請訪問。
For further information, please contact:
欲了解更多信息，請聯繫：
Kris Weinberg, CEO
678-429-5582
kris.weinberg@telodx.com
MaRS Centre, South Tower,
101 College Street, Suite 200, Toronto,
ON, M5G 1L7
首席執行官克里斯·溫伯格
678-429-5582
kris.weinberg@telodx.com
MarS 中心、南塔、
多倫多大學街 101 號 200 號套房
不是，M5G 1L7
Cautionary Note Regarding Forward-Looking Statements
關於前瞻性陳述的警示說明
Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "intends", "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements regarding the clinical efficacy of products, commercial viability of products, use of proceeds, and the ability of the TeloView platform to deliver personalized medicine resulting in better treatments and outcomes are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
根據加拿大證券立法，此處包含的某些信息可能構成 “前瞻性信息”。通常，前瞻性信息可以通過使用前瞻性術語來識別，例如 “打算”、“意願”，或者某些行動、事件或結果 “將” 發生的詞語和短語或陳述的變體。關於產品臨床療效、產品的商業可行性、收益用途和TeloView能力的前瞻性陳述 提供個性化藥物以改善治療和療效的平台基於公司的估計，受已知和未知的風險、不確定性和其他因素的影響，這些因素可能導致公司的實際業績、活動水平、業績或成就與此類前瞻性陳述或前瞻性信息（包括資本支出和其他成本）所表達或暗示的結果存在重大差異。無法保證此類陳述會被證明是準確的，因爲實際結果和未來事件可能與此類陳述中的預期存在重大差異。因此，讀者不應過分依賴前瞻性陳述和前瞻性信息。除非適用的證券法要求，否則公司不會更新此處以引用方式納入的任何前瞻性陳述或前瞻性信息。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。